News about Global Pharma

Alembic Pharmaceuticals Gets USFDA Final Approval for Divalproex Sodium Delayed-Release Capsules

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc.

Global Pharma | 16/01/2025 | By Aishwarya |  412

Piramal Pharma to Operate its Digwal Facility on Biomass Briquettes to Promote Sustainability

This achievement marks a substantial step toward Piramal's sustainability goal to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 42 percent by 2030.

Global Pharma | 16/01/2025 | By Aishwarya |  1001

DFE Pharma Expands DPI Expertise at Hyderabad C2F Center to Boost Respiratory Drug Development

The C2F center supports global pharmaceutical companies to bring their products to market faster and more efficiently.

Global Pharma | 15/01/2025 | By Abha |  880

ORIC Pharmaceuticals Signs Clinical Supply Deal with Janssen Research and Development

Under the terms of the agreement, ORIC® will conduct and sponsor the trial and Johnson & Johnson will provide SC amivantamab.

Global Pharma | 15/01/2025 | By Aishwarya |  438

PAG Acquires Majority Stake in Pravesha Industries to Boost Pharma Packaging Footprint

Pravesha produces more than 15,000 metric tons of plastic bottles, closures, and drums and more than two billion units of cartons, labels, and leaflets annually for some of the world’s largest pharmaceutical companies. <br />

Global Pharma | 15/01/2025 | By Abha |  773

AbbVie and REGENXBIO Update on ABBV-RGX-314 Clinical Program

AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.

Global Pharma | 15/01/2025 | By Aishwarya |  481

Vascarta Partners with CUNY to Enhance Chemotherapy Efficacy and Safety

Vascarta has secured exclusive rights to a novel linker chemistry developed by the City College of New York (CUNY) for creating cancer therapies that enhance efficacy and reduce side effects by linking chemotherapeutic agents with curcumin.

Global Pharma | 14/01/2025 | By Manvi |  157

FDA Accepts Biologics License Application for Leqembi Subcutaneous Autoinjector

BioArctic AB announced that the FDA has accepted its partner Eisai's Biologics License Application for Leqembi's subcutaneous autoinjector, potentially enabling at-home maintenance dosing for early-stage Alzheimer's disease.

Global Pharma | 14/01/2025 | By Manvi |  399

Cycle Pharma Acquires Banner Life Sciences

BAFIERTAM will become Cycle’s second branded product for the treatment of MS alongside TASCENSO ODT® (fingolimod).

Global Pharma | 14/01/2025 | By Aishwarya |  1155

Salarius Pharmaceuticals Signs Definitive Merger Agreement with Decoy Therapeutics

Decoy’s product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications.

Global Pharma | 14/01/2025 | By Aishwarya |  403